Oral contraceptives and liver hemangioma: a case-control study
Source: Acta Obstetricia et Gynecologica Scandinavica, Volume 83, Number 12, December 2004 , pp. 1199-1201(3)
Publisher: Informa Healthcare
To study whether there is an epidemiological association between liver hemangiomas and oral contraception use, as may be suggested by clinical observations of liver hemangioma growth during pregnancy and under estrogen administration. Methods.
A case-control study of 40 women with liver hemangiomas, as diagnosed by imaging studies [ultrasonography (US) or computed tomography (CT) and nuclear scan], and 109 age-matched control with normal studies. The women were interviewed with respect to their menstrual, reproductive and oral contraception use history. Results.
The liver hemangioma and control groups did not differ significantly with regard to their menstrual or reproductive history. Ever oral contraception use was reported by 30% of the cases and 27% of controls. The odds ratio (OR) was 1.1 [95% confidence interval (CI) 0.52–2.60] for ever use, 1.64 (95% CI 0.37–7.13) for initiation before the age of 20, and 0.62 (95% CI 0.16–2.42) for use duration of less than 1 year. On the multivariate analysis only the women's age emerged as a predictor for liver hemangiomas (OR 3.1; 95% CI 1.16–8.96). Conclusions.
In this study liver hemangiomas were not associated with menstrual, reproductive and oral contraception use history.
Document Type: Research Article
Affiliations: 1: Department of Obstetrics and Gynecology, 2: Department of Radiology, 3: Nuclear Medicine Institute and 4: Institute for Epidemiology Research, Barzilai Medical Center, Faculty of Health Sciences, Ben-Gurion University of the Negev, Ashkelon, Israel
Publication date: December 1, 2004